BIOPHARMACEUTICAL INDUSTRY AND INTERRELATED BIOTECHNOLOGY ORGANIZATIONS

whitePaper | December 14, 2022

Within the drug development process, there are several steps that occur between the laboratory and final manufacture of the drug product.

whitePaper | November 4, 2019

Revenues from biologics increased by 70% from 2011 to 2016. Biologics account for 20-22% of total pharmaceutical spending. IQVIA estimates US biologics spending will reach $320bn by 2023

whitePaper | July 25, 2022

The goal of each process step is to facilitate the production of a consistent product with high yield, quality, purity, and functionality. Throughout each step various Process Analytical Tools (PAT) are used to ensure quality and production metrics are maintained.

whitePaper | November 24, 2022

Smallpox was the first infectious disease for which an effective vaccine was developed. In the late 1700s, British doctor Edward Jenner devised a method to inoculate people with cowpox pus to give them immunity against smallpox, a much more deadly disease.

whitePaper | December 16, 2022

Cell and gene therapies (CGTs) are continuing to gain momentum in life sciences globally. However, Asia Pacific (APAC) has demonstrated the most growth in CGT developers of any other region, with a rise of 10% in H1 2022 compared to 2021.1

whitePaper | June 5, 2022

The past decade has seen a significant shift in the nature of the products being manufactured and sold by the innovative biopharmaceutical (biopharma) industry. The global biopharmaceutical portfolio of today reflects increased therapeutic competition, a greater prevalence of large molecule drugs, expansion in the number of personalized or targeted products, and a rise of treatments for many orphan diseases.